Definium Therapeutics

Q2 FY2026 EarningsQ2 FY26 results significantly missed consensus on profitability metrics, primarily due to a non-cash $86.2M warrant liability charge. GAAP EPS of -$1.44 missed the -$0.53 mean estimate, while total operating expenses of $75.1M rose 83.5% YoY. Despite the bottom-line miss, the company bolstered its balance sheet to $1.1B in cash following an $805M public offering, extending its runway into 2030, and reported positive Phase 3 MDD data.